Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in plasma) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
August 1, 2023
Assignee:
3D MEDICINES (BEIJING) CO., LTD.
Inventors:
John Gong, Yihui Lin, Fengqing Li, Fangqiang Tang
Abstract: The present invention provides a compound exemplified by Formula I: a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
June 7, 2022
Assignee:
3D MEDICINES (BEIJING) CO., LTD.
Inventors:
John Gong, Yihui Lin, Fengqing Li, Fangqiang Tang
Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
Type:
Application
Filed:
November 17, 2017
Publication date:
February 6, 2020
Applicant:
3D Medicines (Beijing) Co., Ltd.
Inventors:
JOHN GONG, YIHUI LIN, FENGQING LI, FANGQIANG TANG
Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in plasma) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
Type:
Application
Filed:
November 17, 2017
Publication date:
December 5, 2019
Applicant:
3D MEDICINES (BEIJING) CO., LTD.
Inventors:
JOHN GONG, YIHUI LIN, FENGQING LI, FANGQIANG TANG